カテゴリ： GlobalData, アメリカ, 企業調査

Juno Therapeutics Inc：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Juno Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C3332
◆発行会社（調査会社）：GlobalData
◆発行日：2018年8月
◆ページ数：103
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Juno Therapeutics Inc (Juno) is a clinical-stage company that develops novel cellular immunotherapies. The company formulates cell-based cancer immunotherapies based on platforms such as chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to identify and kill cancer cells. It develops CD19 CAR and WT-1 TCR clinical programs which include numerous product candidates in clinical development for several hematologic malignancies in adults and children. Juno offers CAR and TCR product candidates targeting multiple cancer types. The company is evaluating its pipeline candidates for the treatment of relapsed/refractory (r/r) Chronic Lymphocytic Leukemia (CLL), r/r B-Cell Non-Hodgkin’s Lymphoma (NHL); r/r Acute Lymphoid Leukemia (ALL). It works in collaboration with various cancer centers. Juno is headquartered in Seattle, Washington, the US.

Juno Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Juno Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 15
Venture Financing 15
JW Therapeutics Raises USD90 Million in Series A Financing 15
AbViro Raises USD0.4 Million in Venture Financing 16
Juno Therapeutics Raises USD134 Million in Series B Financing 17
Juno Therapeutics Raises US$31 Million In Extended Series A Financing 18
Juno Therapeutics Raises US$145 Million In Series A Financing 19
AbVitro Raises US$0.75 Million In Venture Financing 21
AbVitro Secures USD5.5 Million in Venture Funding from Sante Ventures 22
X-BODY Raises Additional US$0.6 Million In Venture Financing 23
Partnerships 24
Seattle Children’s Hospital to Enter into Agreement with Juno Therapeutics 24
Juno Therapeutics Forms Joint Venture with WuXi AppTec 25
Juno Therapeutics and Fred Hutchinson Cancer Research Center Enter into Joint Venture 26
Celgene Exercises Option Agreement with Juno Therapeutics 27
Juno Therapeutics Enters into Research Agreement with Editas Medicine 28
MedImmune Enters into Agreement with Juno Therapeutics 29
Juno Therapeutics Enters into Research Agreement with FHCRC 30
X-Body BioSciences Enters Into Co-Development Agreement With Jiangsu Hengrui Medicine For AMD 31
Licensing Agreements 32
Juno Therapeutics Enters into Licensing Agreement with Thermo Fisher Scientific 32
Juno Therapeutics Enters into Licensing Agreement with Eli Lilly 33
Juno Therapeutics Enters into Licensing Agreement with Oncotracker 34
Juno Therapeutics Enters into Licensing Agreement with Fred Hutchinson Cancer 35
Juno Therapeutics Enters into Licensing Agreement with MSK and Eureka Therapeutics 36
Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics 37
Juno Therapeutics Enters into Research Collaboration and Licensing Agreement with Fate Therapeutics 38
Juno Therapeutics Amends its Licensing Agreement with Opus Bioc 40
Vernalis Enters into Licensing Agreement with RedoxTherapies 41
Juno Therapeutics Enters into Licensing Agreement with St. Jude Children’s Research Hospital 42
Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center 43
Juno Therapeutics Enters into Licensing Agreement with FHCRC 44
Juno Therapeutics Enters into Licensing Agreement with Trianni 45
Celgene Enters into Licensing Agreement with Juno Therapeutics 46
Equity Offering 47
Juno Therapeutics Raises USD287.6 Million in Public Offering of Shares 47
Juno Therapeutics Raises USD304 Million in IPO 49
Juno Therapeutics Raises USD133.7 Million in Private Placement of Series B Preferred Shares 51
Juno Therapeutics Raises USD31.31 Million in Private Placement of Series A-2 Preferred Shares 52
Juno Therapeutics Raises USD31.3 Million in Private Placement of Series A-2 Preferred Shares 53
Asset Transactions 54
Roche Acquires PETE Technology from AbVitro 54
Acquisition 55
Celgene Acquires Juno Therapeutics for USD9 Billion 55
Juno Therapeutics Acquires RedoxTherapies 57
Juno Therapeutics Acquires AbVitro 58
Juno Therapeutics Acquires X-BODY 59
AstraZeneca May Acquire Juno Therapeutics 60
Juno Therapeutics Acquires Remaining 95.24% Stake in Stage Cell Therapeutics 61
Juno Therapeutics Acquires ZetaRx BioSciences 62
Juno Therapeutics Inc – Key Competitors 63
Juno Therapeutics Inc – Key Employees 64
Juno Therapeutics Inc – Locations And Subsidiaries 65
Head Office 65
Other Locations & Subsidiaries 65
Joint Venture 65
Recent Developments 66
Strategy And Business Planning 66
Sep 21, 2017: Juno Therapeutics Opens New Headquarters and Research Center 66
Financial Announcements 67
Nov 01, 2017: Juno Therapeutics Reports Third Quarter 2017 Financial Results 67
Aug 03, 2017: Juno Therapeutics Reports Second Quarter 2017 Financial Results 70
May 04, 2017: Juno Therapeutics Reports First Quarter 2017 Financial Results 72
Mar 01, 2017: Juno Therapeutics Reports Fourth Quarter and 2016 Financial Results 74
Corporate Communications 78
Jan 05, 2018: Juno Therapeutics Names Cindy Elkins as Chief Information Officer 78
Nov 27, 2017: Juno Therapeutics Appoints Ann L. Lee as Executive Vice President of Technical Operations and Patrick Y. Yang as Executive Vice President, Senior Advisor to the CEO 79
May 23, 2017: Juno Therapeutics Appoints Jay Flatley to Board of Directors 80
Apr 19, 2017: Juno Therapeutics Appoints Rupert Vessey to Board of Directors 81
Apr 17, 2017: Juno Therapeutics Appoints Sunil Agarwal as President of Research and Development 82
Jan 27, 2017: Juno Therapeutics Appoints Corsee D. Sanders as Executive Vice President and Head of Development Operations 83
Legal and Regulatory 84
Jan 12, 2018: Juno Therapeutics Investigation By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Juno Therapeutics, Inc. – JUNO 84
Government and Public Interest 85
Aug 09, 2017: Editas Medicine Achieves Milestone Under Juno Therapeutics Collaboration for Technical Progress Towards Overcoming the Tumor Microenvironment 85
Product News 86
12/12/2017: Juno Therapeutics Highlights Data and Presentations Supporting Best-in-Class Strategy for JCAR017 at ASH 86
12/09/2017: Juno Therapeutics Highlights Key Translational Insights with JCAR017 in Patients with DLBCL 88
11/01/2017: Juno Therapeutics to Highlight New Advances of Anti-Neoplastic Drug Candidate JCARH125 at ASH Conference 89
Oct 11, 2017: New insights into CAR T-cell therapy’s potential side effects 91
06/05/2017: Juno Therapeutics Presents Updated TRANSCEND NHL 001 Trial Data Demonstrating High Durable Response Rates in Patients with Relapsed or Refractory CD19+ Aggressive Non-Hodgkin Lymphoma 93
Clinical Trials 95
Dec 11, 2017: Juno Therapeutics and Celgene Corporation Release Additional Data from TRANSCEND Trial of JCAR017 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma 95
Nov 01, 2017: Juno Therapeutics to Showcase Promising Data from JCAR-017 Product Development Program at ASH Conference 97
Jun 17, 2017: Juno Therapeutics Presents TRANSCEND NHL 001 Trial Data at International Conference on Malignant Lymphoma 99
May 17, 2017: Juno Therapeutics to Present Key Clinical Data Updates on JCAR017 at the 2017 American Society of Clinical Oncology Annual Meeting 101
May 09, 2017: First-In-Human Clinical Trial Aims to Extend Remission for Children and Young Adults With Leukemia Treated With T-Cell Immunotherapy 102
Appendix 103
Methodology 103
About GlobalData 103
Contact Us 103
Disclaimer 103

List of Tables
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Juno Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Juno Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 11
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
JW Therapeutics Raises USD90 Million in Series A Financing 15
AbViro Raises USD0.4 Million in Venture Financing 16
Juno Therapeutics Raises USD134 Million in Series B Financing 17
Juno Therapeutics Raises US$31 Million In Extended Series A Financing 18
Juno Therapeutics Raises US$145 Million In Series A Financing 19
AbVitro Raises US$0.75 Million In Venture Financing 21
AbVitro Secures USD5.5 Million in Venture Funding from Sante Ventures 22
X-BODY Raises Additional US$0.6 Million In Venture Financing 23
Seattle Children's Hospital to Enter into Agreement with Juno Therapeutics 24
Juno Therapeutics Forms Joint Venture with WuXi AppTec 25
Juno Therapeutics and Fred Hutchinson Cancer Research Center Enter into Joint Venture 26
Celgene Exercises Option Agreement with Juno Therapeutics 27
Juno Therapeutics Enters into Research Agreement with Editas Medicine 28
MedImmune Enters into Agreement with Juno Therapeutics 29
Juno Therapeutics Enters into Research Agreement with FHCRC 30
X-Body BioSciences Enters Into Co-Development Agreement With Jiangsu Hengrui Medicine For AMD 31
Juno Therapeutics Enters into Licensing Agreement with Thermo Fisher Scientific 32
Juno Therapeutics Enters into Licensing Agreement with Eli Lilly 33
Juno Therapeutics Enters into Licensing Agreement with Oncotracker 34
Juno Therapeutics Enters into Licensing Agreement with Fred Hutchinson Cancer 35
Juno Therapeutics Enters into Licensing Agreement with MSK and Eureka Therapeutics 36
Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics 37
Juno Therapeutics Enters into Research Collaboration and Licensing Agreement with Fate Therapeutics 38
Juno Therapeutics Amends its Licensing Agreement with Opus Bioc 40
Vernalis Enters into Licensing Agreement with RedoxTherapies 41
Juno Therapeutics Enters into Licensing Agreement with St. Jude Children’s Research Hospital 42
Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center 43
Juno Therapeutics Enters into Licensing Agreement with FHCRC 44
Juno Therapeutics Enters into Licensing Agreement with Trianni 45
Celgene Enters into Licensing Agreement with Juno Therapeutics 46
Juno Therapeutics Raises USD287.6 Million in Public Offering of Shares 47
Juno Therapeutics Raises USD304 Million in IPO 49
Juno Therapeutics Raises USD133.7 Million in Private Placement of Series B Preferred Shares 51
Juno Therapeutics Raises USD31.31 Million in Private Placement of Series A-2 Preferred Shares 52
Juno Therapeutics Raises USD31.3 Million in Private Placement of Series A-2 Preferred Shares 53
Roche Acquires PETE Technology from AbVitro 54
Celgene Acquires Juno Therapeutics for USD9 Billion 55
Juno Therapeutics Acquires RedoxTherapies 57
Juno Therapeutics Acquires AbVitro 58
Juno Therapeutics Acquires X-BODY 59
AstraZeneca May Acquire Juno Therapeutics 60
Juno Therapeutics Acquires Remaining 95.24% Stake in Stage Cell Therapeutics 61
Juno Therapeutics Acquires ZetaRx BioSciences 62
Juno Therapeutics Inc, Key Competitors 63
Juno Therapeutics Inc, Key Employees 64
Juno Therapeutics Inc, Subsidiaries 65
Juno Therapeutics Inc, Joint Venture 65

List of Figures
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

★海外企業調査レポート[Juno Therapeutics Inc：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Raymond James Financial Inc：戦略・SWOT・企業財務分析
    Raymond James Financial Inc - Strategy, SWOT and Corporate Finance Report Summary Raymond James Financial Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • MGB Biopharma Ltd-製薬・医療分野：企業M&A・提携分析
    Summary MGB Biopharma Ltd (MGB) is a clinical stage biopharmaceutical company which develops anti-infective medicine of minor groove binder (MGBs) compounds. The company focuses on the development of new class of small molecules, with specific antibacterial activity against susceptible and resistant …
  • Tokio Marine Holdings, Inc.：企業の戦略・SWOT・財務情報
    Tokio Marine Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Tokio Marine Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • The Northwestern Mutual Life Insurance Company：戦略・SWOT・企業財務分析
    The Northwestern Mutual Life Insurance Company - Strategy, SWOT and Corporate Finance Report Summary The Northwestern Mutual Life Insurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • Eagle Oil & Gas Co：石油・ガス：M&Aディール及び事業提携情報
    Summary Eagle Oil & Gas Co (Eagle Oil) is an oil and gas company that acquires, develops, regulates, and explores oil and gas reserves. The company offers contract drilling services. It undertakes projects such as Haynesville, Oklahoma stack, West Raymond Field, Marcellus, Woodford, Lower Cotton Val …
  • Dino Polska S.A (DNP)：企業の財務・戦略的SWOT分析
    Dino Polska S.A (DNP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Trivitron Healthcare Pvt Ltd：医療機器：M&Aディール及び事業提携情報
    Summary Trivitron Healthcare Pvt Ltd (Trivitron) is a medical technology company that provides solutions to healthcare providers. The company’s products include radiography and c-arm systems, newborn screening, mammography, ultrasound, contrast media, breast biopsy system, bone densitometer, radiati …
  • Univalor Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Univalor Inc (Univalor) is a university technology transfer organization that optimizes research outcomes by commercializing the technological innovations of researchers from health centers and academic institutions. The organization provides researcher services such as protecting intellectu …
  • Shaw Communications Inc (SJR.B)：企業の財務・戦略的SWOT分析
    Shaw Communications Inc (SJR.B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Collegium Pharmaceutical Inc (COLL)：医療機器：M&Aディール及び事業提携情報
    Summary Collegium Pharmaceutical Inc (Collegium) is a specialty pharmaceutical company that focuses on the development and commercialization of innovative products for treating patients suffering from pain. The company develops products based on its DETERx platform technology. DETERx offers extended …
  • Bioton SA (BIO)：企業の財務・戦略的SWOT分析
    Bioton SA (BIO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • PharmAust Ltd (PAA)-製薬・医療分野：企業M&A・提携分析
    Summary PharmAust Ltd (PharmAust) is a drug discovery and development company which provides human and veterinary proprietary medicines to treat different types of cancers. The company provides specialized medicinal and synthetic chemistry services. It specializes in bio defense and laboratory suppo …
  • The AES Corporation：発電所・企業SWOT分析
    The AES Corporation – Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • P.F. Chang’s China Bistro, Inc.：企業の戦略・SWOT・財務情報
    P.F. Chang's China Bistro, Inc. - Strategy, SWOT and Corporate Finance Report Summary P.F. Chang's China Bistro, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Edenred SA (EDEN)：企業の財務・戦略的SWOT分析
    Edenred SA (EDEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Modern India Ltd：企業の戦略・SWOT・財務情報
    Modern India Ltd - Strategy, SWOT and Corporate Finance Report Summary Modern India Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • UCB SA (UCB)：医療機器：M&Aディール及び事業提携情報
    Summary UCB SA (UCB) is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat various diseases. It principally focuses on developing products for the treatment of central nervous system (CNS) and immunology related conditions. The company's key medicines …
  • Ahimsa Industries Limited：企業の戦略・SWOT・財務情報
    Ahimsa Industries Limited - Strategy, SWOT and Corporate Finance Report Summary Ahimsa Industries Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • ABM Industries Incorporated：企業の戦略・SWOT・財務分析
    ABM Industries Incorporated - Strategy, SWOT and Corporate Finance Report Summary ABM Industries Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Whirlpool Of India Limited：企業の戦略・SWOT・財務情報
    Whirlpool Of India Limited - Strategy, SWOT and Corporate Finance Report Summary Whirlpool Of India Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆